Robin Sukhia has been an essential bridge between India and Sweden since 1996 when, through a Swedish venture capital company, he invested in India. He helps Swedish corporates and government institutions understand and navigate India when the need arises. Most recently, Robin and his agency facilitated a collaboration between India’s Serum Institute and British-Swedish pharma giant AstraZeneca for the COVID-19 vaccine.